



Programme Book

13 - 15 September 2023

ecth.org



ECTH 2023

European Congress on
Thrombosis and Haemostasis

Valencia, Spain

Table of Contents

Congress General Information	3
Scientific Programme	4
Networking Events	5
Floorplan.....	6
Programme at a Glance	8
Wednesday 13 September	14
Thursday 14 September	26
Friday 15 September	43
Posters	52

Congress General Information

Venue

Valencia Conference Centre (Palacio de Congresos de Valencia)
Avda. Cortes Valencianas, nº 60
46015 València

Registration hours

The registration desk, located on the ground floor in the foyer, will be open during the following days:

Wednesday	13 September	08.00 - 18.00 hours
Thursday	14 September	08.30 - 18.30 hours
Friday	15 September	08.30 - 14.00 hours

Badges

All participants will receive a personal badge upon registration. You are kindly requested to wear your name badge at all times, during scientific meetings and social gatherings. Only participants who are wearing their name badge will be admitted to the congress.

Catering

Food and beverages will be served in the Network area, located in the foyer of the ground floor.

Insurance

The congress organiser cannot accept responsibility for accidents that might occur. Delegates are encouraged to obtain travel insurance (medical, personal accident and luggage) in their home country prior to departure.

Internet

WiFi is available in the congress related areas. The network and username is: **ECTH2023** and the password is **valencia**.

Lost and Found

All lost and found items can be collected at the registration desk.

General Information Regarding The Scientific Programme

Important notice for moderators and speakers

All moderators and speakers are kindly requested to be in the session room at least 15 minutes before the beginning of the session.

Abstracts

All abstracts are listed in the online Abstract Book, available at the congress website.

EBAH CME accreditation

The programme of the 2nd European Congress on Thrombosis and Haemostasis has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of 23 CME credits.

Certificates of attendance

Certificates of attendance will be sent by email, shortly after the congress.

Speaker Ready Room

The Speaker Ready Room is located next to Auditorium 2, located on the ground floor. Speakers are requested to bring their presentations to the SRR on a USB stick at least 1-hour prior to the session starts. The use of your own laptop during your presentation is NOT possible.

Opening hours of the SRR:

Wednesday	13 September	08.00 - 18.00 hours
Thursday	14 September	08.30 - 17.00 hours
Friday	15 September	08.30 - 13.30 hours

Programme changes

The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

Networking Events

Opening ceremony

Wednesday 13 September
17.30 - 18.00 hours
Auditorium 2

All delegates and sponsors are welcome to attend.

Welcome reception

18.00 - 19.00 hours
Network area

All delegates and sponsors are welcome to attend.

Poster reception

Thursday 14 September
17.00 - 18.30 hours
Poster session area

Take advantage of the guided sessions - choose the most interesting group and be on time.


Congress party

Thursday 14 September
18.30 - 00.00 hours


Join us for an exceptional party at the former **Carthusian Monastery**, located just outside Valencia. Enjoy Spanish dishes, drinks and dance the night away at this stunning location!

Busses will depart at 18:30 and return as of 22:00 from and back to the Valencia Conference Centre.
Price: € 85 per person (*to be purchased at the registration desk*)


GROUND FLOOR



FIRST FLOOR



FIRST FLOOR



Wednesday 13 September 2023

	Auditorium 2	Auditorium 3	Multifunctional A	Multifunctional B
09.00 - 10.00	Spanish Society of Thrombosis and Haemostasis (SETH)			
10.00 - 10.30	Coffee Break & Poster Viewing			
10.30 - 12.15	Spanish Society of Thrombosis and Haemostasis (SETH)			
12.15 - 13.15	Lunch Break			
13.15 - 14.45	Thrombotic Risk Factors	Vessel Wall Biology	Neutrophil ExtraCellular Traps	Platelet Biology
14.45 - 15.00	Short Break & Poster Viewing			
15.00 - 16.00	Plenary Arts and Medicine			
16.00 - 16.30	Coffee Break & Poster Viewing			
16.30 - 17.30	Science Fast and Furious			
17.30 - 18.00	Opening Ceremony			
18.00 - 19.00	Welcome Reception (Network Area)			

	Plenary Session		Science, Fast and Furious
	Bleeding		SETH Sessions
	Clotting		Other Sessions
	Platelets		
	Vessel Wall		
	State of the Art		

Thursday 14 September 2023

	Auditorium 2	Auditorium 3	Multifunctional A	Multifunctional B
09.00 - 09.30	Meet the Expert (Network Area)			
09.30 - 10.00	Coffee Break & Poster Viewing			
10.00 - 11.00	Focus Symposium Antithrombin	Focus Symposium Inflammation and NETs	Focus Symposium Bleeding in Women	Focus Symposium Platelets Receptors & Mechanisms
11.00 - 11.45	State of the Art Telemedicine and artificial intelligence for joint health monitoring in patients with hemophilia	State of the Art Thrombo-inflammation and Autoimmune-thrombosis		
11.45 - 12.30	State of the Art The role of fibrinogen in acquired bleeding	State of the Art The Spanish national project on inherited platelet disorders		
12.30 - 13.30	Lunch Symposium Treatment of Thrombotic Thrombocytopenic Purpura (TTP)	Lunch Break		
13.30 - 14.30	Plenary The future of hemophilia treatment: benefits and challenges			
14.30 - 15.30	COVID-19 and thrombosis	Risk factors and Biomarkers for Thrombosis	Etiology of Thrombosis	Platelet Aggregation
15.30 - 16.00	Coffee Break & Poster Viewing			
16.00 - 17.00	Focus Symposium Coagulation Genetics	Focus Symposium Aspects of von Willebrand Factor	Focus Symposium Novel Laboratory Tests	Focus Symposium Inflammation and Haemostasis
17.00 - 18.30	Poster Session and Reception (Network Area)			
18.00 - 19.00	Congress Dinner: Carthusian Monastery (offsite). Tickets available at the Registration Service Desk (€ 85)			

	Plenary Session		Science, Fast and Furious
	Bleeding		SETH Sessions
	Clotting		Other Sessions
	Platelets		
	Vessel Wall		
	State of the Art		

Friday 15 September 2023

	Auditorium 2	Auditorium 3	Multifunctional A	Multifunctional B
09.00 - 10.00	Clotting Structure & Function	Venous & Arterial Thrombosis Aspects and Risks	Regulation of Protein Function in Hemostasis	Regulation of Coagulation and Inflammation
10.00 - 10.30				
10.30 - 11.00	State of the Art Fibrin clot properties and thromboembolism	State of the Art Cardiovascular risk factors and venous thromboembolism		
11.00 - 11.30	State of the Art Fibrin(ogen) in human disease	State of the Art Neutrophils at the acute phase of ischemic stroke		
11.30 - 12.30	Science Fast and Furious			
12.30 - 13.30	Lunch Break			
13.30 - 14.30	Plenary Women and thrombosis			
14.30 - 14.45	Closing and ECTH2023			

	Plenary Session		Science, Fast and Furious
	Bleeding		SETH Sessions
	Clotting		Other Sessions
	Platelets		
	Vessel Wall		
	State of the Art		

Wednesday 13 September

09.00 – 10.00

Room: Auditorium 2

**Spanish Society of Thrombosis
and Haemostasis (SETH)**

09.00 – 10.00 PATHOPHYSIOLOGY AND TREATMENT OF VIT.
Pilar Llamas and Nuria Revilla, Spain

09.25 – 09.50 ALTERED HEMOSTASIS IN CHRONIC LIVER DISEASE.
Santiago Bonanad, Spain

09.50 – 10.00 DISCUSSION

10.00 – 10.30 **Coffee Break and Poster Viewing**

Wednesday 13 September

10.30 - 12.15

Room: Auditorium 2

**Spanish Society of Thrombosis
and Haemostasis (SETH)**

10.30 - 11.00 PREVENTION OF VENOUS THROMBOEMBOLISM IN
HEMATOLOGIC NEOPLASMS.
José Ramón González, Spain

11.00 - 11.30 GLOBAL HEMOSTASIS ASSAYS: APPLICATIONS IN
THROMBOTIC DISEASE.
José Antonio Páramo, Spain

11.30 - 12.00 RESOLVING MYSTERIES OF THROMBOINFLAMMATION.
Sonia Águila, Spain

12.00 - 12.15 DISCUSSION

12.15 - 13.15 **Lunch break**

Wednesday 13 September

13.15 - 14.00

Room: Auditorium 2

**Oral Communications:
Thrombotic Risk Factors**

*Moderators: Vårin Wikan (Norway)
& Ingrid Dijkgraaf (The Netherlands)*

13.15 - 13.30 HISTO-BLOOD GROUP ABO SYSTEM TRANSFERASE LEVELS
OR01-02 AND RISK OF VENOUS THROMBOEMBOLISM.
Asbjørn Lund Onsaker, Norway

13.30 - 13.45 THE OCCURRENCE OF THROMBOPHILIC RISK FACTORS
OR01-03 IN PATIENTS WITH CENTRAL RETINAL ARTERY OCCLUSION
AND ITS RELATION TO ULTRASOUND PARAMETERS.
Radosław Dziedzic, Poland

13.45 - 14.00 CORRELATION BETWEEN ETP-BASED APC RESISTANCE AND
OR01-04 THE RELATIVE RISK OF VENOUS THROMBOEMBOLISM IN
WOMEN USING COMBINED ORAL CONTRACEPTIVES.
Laure Morimont, Belgium

Wednesday 13 September

14.00 - 14.30

Room: Auditorium 2

Oral Communications: Thrombotic Risk Factors

*Moderators: Vårin Wilan (Norway)
& Ingrid Dijkgraaf (The Netherlands)*

14.00 - 14.15

OR01-05

TARGETED PANEL GENE SEQUENCING FOR IDENTIFYING RARE VARIANTS ASSOCIATED WITH VENOUS THROMBOEMBOLISM (VTE): APPLICATION TO 139 PATIENTS WITH UNPROVOKED VTE AND NEGATIVE THROMBOPHILIA SCREENING.

Pierre Morange, France

14.15 - 14.30

OR01-06

NET CLINICAL BENEFIT AND COST-EFFECTIVENESS OF INDEFINITE ANTICOAGULATION AMONG CLINICALLY RELEVANT SUBGROUPS OF PATIENTS WITH FIRST UNPROVOKED VENOUS THROMBOEMBOLISM.

Faizan Khan, Canada

Wednesday 13 September

13.15 - 14.15

Room: Auditorium 3

**Oral Communications:
Vessel Wall Biology**

*Moderators: Vanessa Bröker (The Netherlands)
& Kanin Wichapong (The Netherlands)*

13.15 - 13.30 NATIVE VASCULAR EXTRACELLULAR MATRIX COATING FOR
OR02-01 IN VITRO CARDIOVASCULAR MODELS.

Titus Lemmens, The Netherlands

13.30 - 13.45 ENDOTHELIAL P2X7 PROMOTES VENOUS
OR02-02 THROMBOEMBOLISM.

Estelle Ollivier, France

13.45 - 14.00 PART 1 KNOCK OUT IPSCS-DERIVED VASCULAR SMOOTH
OR02-03 MUSCLE CELLS DISPLAY HIGHER TISSUE FACTOR-DEPENDENT
THROMBIN GENERATION COMPARED TO WILD TYPE.

Anxhela Habibi, Germany

14.00 - 14.15 SUSTAINABLE SYNTHETIC POLYMER FOR A MORE
OR02-04 HEMOCOMPATIBLE AND DURABLE PROSTHETIC
AORTIC VALVE.

Sofia Melo, Belgium

Wednesday 13 September

14.15 - 14.45

Room: Auditorium 3

**Oral Communications:
Vessel Wall Biology**

*Moderators: Vanessa Bröker (The Netherlands)
& Kanin Wichapong (The Netherlands)*

14.15 - 14.30 APPLICATION OF METABOLOMICS IN THE STUDY OF NEW
OR02-05 MARKERS OF ATHEROMA PLAQUE INSTABILITY.
Raquel Herranz, Spain

14.30 - 14.45 ACTIVATED PROTEIN C REGULATES ABERRANT
OR02-06 THROMBO-INFLAMMATORY T-CELL ACTIVITY IN
IMMUNOTHROMBOTIC DISEASE.
Gemma Leon, Ireland

Wednesday 13 September

13.15 - 14.15

Room: Multifunctional A

**Oral Communications:
Neutrophil Extracellular Traps**

*Moderators: Willian van Dijk (The Netherlands)
& Isabel Aleman-Cabrera (Spain)*

13.15 - 13.30 PLASMA BIOMARKERS OF NEUTROPHIL EXTRACELLULAR
OR03-01 TRAPS (NETS) LEVELS.

Gaëlle Munsch, France

13.30 - 13.45 POTENTIAL ROLE OF NETOSIS BIOMARKERS IN DISEASE
OR03-02 DIAGNOSIS AND MANAGEMENT IN HIGH-GRADE SEROUS
OVARIAN CANCER.

Julia Oto, Germany

13.45 - 14.00 IMPAIRED BALANCE BETWEEN FORMATION OF NEUTROPHIL
OR03-03 EXTRACELLULAR TRAPS AND THEIR DEGRADATION BY
DNASES IN COVID-19 PATIENTS.

Chloé James, France

14.00 - 14.15 PROTEOLYTIC NEUTRALIZATION OF EXTRACELLULAR
OR03-04 HISTONES BY NEUTROPHIL ELASTASE IS ENHANCED BY
HEPARIN.

Gerry Nicolaes, The Netherlands

Wednesday 13 September

14.15 - 14.45

Room: Multifunctional A

**Oral Communications:
Neutrophil Extracellular Traps**

*Moderators: Willian van Dijk (The Netherlands)
& Isabel Aleman-Cabrera (Spain)*

14.15 - 14.30 PATIENTS WITH PROTEIN C DEFICIENCY HAVE INCREASED
OR03-05 NETOSIS, POSSIBLY MEDIATED BY REDUCED LEVELS OF
CIRCULATING ACTIVATED PROTEIN C.

Maria Castaño, Spain

14.30 - 14.45 EXCESSIVE INTRAHEPATIC NEUTROPHIL ACCUMULATION
OR03-06 AND EXTRACELLULAR TRAP FORMATION IMPEDES LIVER
REGENERATION AFTER PARTIAL HEPATECTOMY IN MICE
AND HUMANS.

Laura Brunthaler, Austria

Wednesday 13 September

13.15 – 14.30

Room: Multifunctional B

**Oral Communications:
Platelet Biology**

*Moderator: Shaghayegh Rashvand
(United Kingdom)*

- 13.15 – 13.30** PROTEIN DISULFIDE ISOMERASE 1 AND 3 (PDIA1, PDIA3)
OR04-01 REGULATE PLATELET-DERIVED EXTRACELLULAR VESICLE
(PEV) FORMATION.
Agnieszka Pelesz, Poland
- 13.30 – 13.45** PLATELET AGGREGATION AND PLASMA COAGULATION IN
OR04-02 FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS REQUIRING
SPECIFIC HYPOLIPIDEMIC TREATMENT.
Alejandro Carazo, Czech Republic
- 13.45 – 14.00** PLATELET AGGREGATION IN COLORECTAL CANCER
OR04-03 PATIENTS UNDERGOING SURGERY.
Mikkel Lundbech, Denmark
- 14.00 – 14.15** SOLUBLE AND EXTRACELLULAR VESICLE-BOUND PLASMA
OR04-04 P-SELECTIN AS A DIAGNOSTIC BIOMARKER FOR ACUTE
DEEP VEIN THROMBOSIS.
Omri Snir, Norway
- 14.15 – 14.30** PLATELETS PROMOTE PERI-INFARCT CELL PROLIFERATION
OR04-05 AND VASCULAR INTEGRITY TWO DAYS FOLLOWING
FOCAL CEREBRAL ISCHEMIA.
Sabrina Mavouna, France

Wednesday 13 September

14.30 - 14.45

Room: Multifunctional B

**Oral Communications:
Platelet Biology**

*Moderator: Shaghayegh Rashvand
(United Kingdom)*

14.30 - 14.45

OR04-06

PLATELET-EDUCATED CANCER CELLS
OVEREXPRESS FIBRONECTIN AS WELL AS DIFFERENT
GLYCOSYLTRANSFERASES.

Melanie Langiu, France

14.45 - 15.00 Short Coffee Break and Poster Viewing

15.00 - 16.00

**Plenary Lecture
Room: Auditorium 2**

Moderators: Titus Lemmens (The Netherlands)

ARTS AND MEDICINE.

Christiane Druml, Austria

16.00 - 16.30 Coffee Break and Poster Viewing

Wednesday 13 September

16.30 – 17.30

Room: Auditorium 2

Science, Fast and Furious

Moderator: Tilman Hackeng (The Netherlands)

16.30 – 16.45 A SIGNIFICANT NUMBER OF CASES OF ANTITHROMBIN
SFF01-01 DEFICIENCY DIAGNOSED WITHOUT SERPINC1
DEFECTS ARE DUE TO CONGENITAL DISORDERS OF
GLYCOSYLATION.

María Llamas López, Spain

16.45 – 17.00 TISSUE FACTOR PATHWAY INHIBITOR ATTENUATES
SFF01-02 CALCIUM-INDUCED VASCULAR SMOOTH MUSCLE CELL
CALCIFICATION.

Vanessa Bröker, The Netherlands

17.00 – 17.15 DECREASING MORTALITY RISK IN CANCER-RELATED
SFF01-03 VENOUS THROMBOEMBOLISM OVER THE LAST THREE
DECADES.

Nikolai Hagensen Eide, Norway

17.15 – 17.30 LLAMA-DERIVED SINGLE-DOMAIN ANTIBODIES BLOCKING
SFF01-04 TISSUE FACTOR PATHWAY INHIBITOR AND INCREASING
THROMBIN GENERATION IN FVIII- AND FX-DEFICIENT
PLASMA.

François Saller, France

Wednesday 13 September

17:30 - 18:00

Room: Auditorium 2

I Opening Ceremony

A warm welcome by Frits Rosendaal (The Netherlands); Pilar Medina (Spain); & Juan Carles Reverter Calatayud (Spain).

Find out who has won the BRB Publication Prize offered by Technoclone, as well as the Prix d'honneur de la jeunesse awards!

18:00 - 19:00

Network Area

Welcome Reception

Thursday 14 September

09.00 – 09.30

Foyer

Meet the Expert

SCIENTIFIC INTEGRITY

Frits Rosendaal, The Netherlands

REGULATION OF COAGULATION INITIATION

Tilman Hackeng, The Netherlands

FEMALE COAGULATION DISORDERS

Sabine Eichinger, Austria

Luuk Scheres, The Netherlands

DIVERSITY AND INCLUSIVITY IN THROMBOSIS AND
HAEMOSTASIS

Judith Cosemans, The Netherlands

GENETICS OF THROMBOPHILIA

Pierre Morange, France

RISK FACTORS OF THROMBOSIS

John-Bjarne Hanssen, Norway

NEUTROPHIL EXTRACELLULAR TRAPS

Pilar Medina, Spain



More experts on the next page.

Thursday 14 September

09.00 – 09.30

Foyer

Meet the Expert

HEMOPHILIA TREATMENT

Victor Jiminez-Yuste, Spain

CAREER DEVELOPMENT

Tom van de Berg, The Netherlands

POINT OF CARE TESTING

Waander van Heerde, The Netherlands

MEET THE EDITOR

Suzanne Cannegieter, The Netherlands

ANTITHROMBIN

Javier Corral, Spain

09.30 – 10.00 Coffee Break and Poster Viewing

Thursday 14 September

10.00 - 11.00

Room: Auditorium 2

Focus Symposium - Antithrombin

*Moderators: Bounab Lyamine (Algeria)
& Michelle van der Helm (The Netherlands)*

10.00 - 10.30 EXPLORING NATURE TO GAIN A DEEPER UNDERSTANDING
OR05-01 OF ANTITHROMBIN.

Javier Corral, Spain

10.30 - 10.45 FUNCTIONAL, BIOCHEMICAL, AND CLINICAL DISSECTION
OR05-02 OF GENETIC VARIANTS AFFECTING ARGININES OF THE
HEPARIN-BINDING SITE IN ANTITHROMBIN.

Rosa Cifuentes, Spain

10.45 - 11.00 RECURRENT MUTATIONS IN ANTITHROMBIN DEFICIENCY:
OR05-03 ORIGIN AND EXPANSION; FOUNDER MUTATIONS AND
HOTSPOTS.

Esther Navarro Manzano, Spain

Thursday 14 September

10.00 - 11.00

Room: Auditorium 3

**Focus Symposium -
Inflammation and NETs**

*Moderators: Gerry Nicolaes (The Netherlands)
& Laura Brunnthaler (Austria)*

10.00 - 10.30 NEUTROPHIL EXTRACELLULAR TRAPS IN CANCER, WHAT
OR06-01 DOESN'T KILL YOU MAKES YOU STRONGER.

Pilar Medina, Spain

10.30 - 10.45 THE IMPACT OF HYPOXIC PROFILES AND INFLAMMATION
OR06-02 ON PRIMARY MONOCYTE RESPONSES.

Omri Snir, Norway

10.45 - 11.00 REGULATION OF NETS BY PEPTIDIC INHIBITORS TARGETING
OR06-03 EXTRACELLULAR HISTONES.

Kanin Wichapong, The Netherlands

Thursday 14 September

10.00 – 11.00

Room: Multifunctional A

**Focus Symposium –
Bleeding in Women**

*Moderators: Laure Morimont (Belgium)
& Mark Smeets (The Netherlands)*

10.00 – 10.30 WOMEN-SPECIFIC BLEEDING ON ANTICOAGULANT
OR07-01 THERAPY: AN UPDATE.
Luke Scheres, The Netherlands

10.30 – 10.45 FAMILY HISTORY OF POSTPARTUM HEMORRHAGE IS
OR07-02 A RISK FACTOR FOR POSTPARTUM HEMORRHAGE
AFTER VAGINAL DELIVERY: RESULTS FROM THE FRENCH
PROSPECTIVE MULTICENTER HEMOTHEPP COHORT STUDY.
François ANOUILH, France

10.45 – 11.00 EFFECTS OF ANTIPLATELET THERAPY ON MENSTRUAL BLOOD
OR07-03 LOSS IN PREMENOPAUSAL WOMEN: A SYSTEMATIC REVIEW.
Eva Kempers, The Netherlands

Thursday 14 September

10.00 - 11.00

Room: Multifunctional B

**Focus Symposium –
Platelet Receptors &
Mechanisms**

*Moderators: Judith Cosemans (The Netherlands)
& Tomasz Przygodzki (Poland)*

10.00 - 10.30

OR08-01

GPVI AS AN ATTRACTIVE THERAPEUTIC TARGET.

Pierre Mangin, France

10.30 - 10.45

OR08-02

THE CLEARANCE RECEPTOR CLEC4M REGULATES PLASMA FACTOR V LEVELS THROUGH FACTOR V BINDING AND INTERNALIZATION.

Adarsh K Mohapatra, The Netherlands

10.45 - 11.00

OR08-03

IDENTIFICATION OF POLO-LIKE KINASE 3 IN PLATELETS AND ITS ROLE IN THE REGULATION OF HEMOSTASIS AND THROMBOSIS.

Meghna Naik, United States

Thursday 14 September

11.00 – 12.30

State of the Art

Room: Auditorium 2

*Moderators: Hong Hoe Koo (South Korea)
& Robert Ariens (United Kingdom)*

- 11.00 – 11.45** TELEMEDICINE AND ARTIFICIAL INTELLIGENCE FOR JOINT HEALTH MONITORING IN PATIENTS WITH HEMOPHILIA.
Roberta Gualtierotti, University of Milan, Italy
- 11.45 – 12.30** THE ROLE OF FIBRINOGEN IN ACQUIRED BLEEDING.
Nicola Curry, Oxford University Hospital, United Kingdom

State of the Art

Room: Auditorium 3

*Moderator: Raquel Herranz (Spain)
& Agnieszka Pelesz (Poland)*

- 11.00 – 11.45** THROMBO-INFLAMMATION AND AUTOIMMUNE-THROMBOSIS.
Wolfram Ruf, University of Mainz, Germany
- 11.45 – 12.30** THE SPANISH NATIONAL PROJECT ON INHERITED PLATELET DISORDERS.
Jose Rivera, University of Murcia, Spain

Thursday 14 September

12.30 – 14.30

Lunch discussion: TTP
Room: Auditorium 2

Moderator: Frits Rosendaal (The Netherlands)

12.30 – 13.30

TREATMENT OF TTP WITH CAPLACIZUMAB: TRIAL EVIDENCE.

Andrea Artoni, Italy

HOW TO TREAT ITTP IN 2023 – THE CLINICIAN'S POINT OF VIEW.

Paul Brinkkötter, Germany

OBTAINING REAL WORLD EVIDENCE IN RARE DISORDERS AS TTP.

Javier Cid, Spain

12.30 – 13.30

Lunch Break

13.30 – 14.30

Plenary Lecture
Room: Auditorium 2

*Moderators: Pierre Morange (France)
& Danique Steeghs (The Netherlands)*

THE FUTURE OF HEMOPHILIA TREATMENT: BENEFITS AND CHALLENGES.

Victor Jimenez Yuste, La Paz University Hospital, Madrid, Spain

Thursday 14 September

14.30 – 15.30

Room: Auditorium 2

**Oral Communications:
COVID-19 and thrombosis**

*Moderators: Chloé James (France)
& Tom van de Berg (The Netherlands)*

- 14.30 – 14.45** EFFECT OF SARS-COV-2 MRNA VACCINATION ON
OR09-01 THROMBIN GENERATION AND DISEASE ACTIVITY IN
CHILDREN WITH INFLAMMATORY BOWEL DISEASE.
Vivien Stercel, Hungary
- 14.45 – 15.00** TRANSIENT AUTOREACTIVE ANTIBODIES IN PROSPECTIVELY
OR09-02 SAMPLED COVID-19 VACCINE RECIPIENTS.
Chantal Visser, The Netherlands
- 15.00 – 15.15** SARS-COV-2 VACCINATION AND RISK OF VENOUS
OR09-03 THROMBOSIS – CASE CONTROL STUDY ON ROUTINE CARE
DATA FROM DUTCH GENERAL PRACTITIONERS.
Willian van Dijk, The Netherlands
- 15.15 – 15.30** THE MAIN PROTEASE (MPRO) FROM SARS-COV-2
OR09-04 TRIGGERS PLASMA COAGULATION BY ACTIVATING FVII
AND FXI.I.
Vincenzo De Filippis, Italy

Thursday 14 September

14.30 - 15.30

Room: Auditorium 3

**Oral Communications:
Risk factors and Biomarkers for
Thrombosis**

*Moderators: Sigrid K. Brækkan (Norway)
& Nikolai Eide (Norway)*

14.30 - 14.45 HIGH PLASMA EXPRESSION LEVELS OF MICRORNA-145
OR10-01 ARE ASSOCIATED WITH REDUCED RISK OF FUTURE VENOUS
THROMBOEMBOLISM.

Vania M. Morelli, Norway

14.45 - 15.00 02 IDENTIFICATION OF A TARGETED PLASMA PROTEIN
OR10-02 SIGNATURE TO PREDICT RECURRENT VENOUS
THROMBOEMBOLISM AND DEATH.

Alejandro Pallares Robles, Germany

15.00 - 15.15 PREDICTIVE RISK FACTORS FOR POST THROMBOTIC
OR10-03 SYNDROME IN INFANTS AND CHILDREN.

Irene Klaassen, The Netherlands

15.15 - 15.30 METABOLIC AND EPIGENETIC PERTURBATIONS UNDERLIE
OR10-04 MALADAPTIVE TRAINED IMMUNITY-ASSOCIATED MYELOID
CELL HYPERCOAGULABILITY.

Aisling Rehill, Ireland

Thursday 14 September

14.30 – 15.30

Room: Multifunctional A

**Oral Communications:
Etiology of Thrombosis**

*Moderators: Alessia Dei Rossi (Italy)
& Aleksandar Dishkelov (United Kingdom)*

14.30 – 14.45 ADP-DEPENDENT PLATELET ACTIVATION IS IMPORTANT IN
OR11-01 THE DEVELOPMENT OF VENOUS THROMBOSIS DURING A
LONG-DISTANCE FLIGHT.

Julie Tourn, France

14.45 – 15.00 LENGTH OF ISCHAEMIA DURATION IS ASSOCIATED
OR11-02 WITH FIBRIN FILM COVERAGE OF ACUTE MYOCARDIAL
INFARCTION THROMBI.

Cédric Duval, United Kingdom

15.00 – 15.15 HUMAN TRANSTHYRETIN AMYLOID FIBRILS INDUCE PLASMA
OR11-03 CLOTTING BY ACTIVATING THE INTRINSIC PATHWAY
OF BLOOD COAGULATION: IMPLICATIONS IN THE
PATHOGENESIS OF HTTR INTRACARDIAC THROMBOSIS.

Vincenzo De Filippis, Italy

15.15– 15.30 GARDOS CHANNEL INHIBITOR PREVENTS AN ENHANCED
OR11-04 EXPERIMENTAL VENOUS THROMBOSIS IN SICKLE TRAIT
MICE.

Rafal PAWLINSKI, United States

Thursday 14 September

14.30 – 15.30

Room: Multifunctional B

**Oral Communications:
Platelet Aggregation**

*Moderators: Sabrina Mavouna (France)
& Paola Van der Meijden (The Netherlands)*

14.30 – 14.45 EFFECTS OF RED BLOOD CELL HEMOLYSATE,
OR12-01 UNCONJUGATED BILIRUBIN AND FAT EMULSION ON LIGHT
TRANSMISSION PLATELET AGGREGATION USING TA-8V
INSTRUMENT.

Gaia Zirka, France

14.45 – 15.00 PLATELET ACTIVATION INDUCED BY CPG-RICH
OR12-02 OLIGODEOXYNUCLEOTIDES: THE INVOLVEMENT OF THE
C-TYPE LECTIN RECEPTOR CD93.

Silvia Maria Grazia Trivigno, Italy

15.00 – 15.15 APPLICATION OF THE MACHINE LEARNING-BASED IMAGE
OR12-03 ANALYSIS IN THE QUANTIFICATION OF THROMBI IN FLOW
CHAMBER ASSAYS.

Tomasz Przygodzki, Poland

15.15– 15.30 DIFFERENTIAL ANTIPLATELET EFFECTS OF A NEW INHIBITOR
OR12-04 OF PDI ISOMERASES – C-3399.

Kamil Przyborowski, Poland

15.30 – 16.00 Coffee Break and Poster Viewing

Thursday 14 September

16.00 – 17.00

Room: Auditorium 2

**Focus Symposium –
Coagulation Genetics**

Moderator: María Llamas López (Spain)

16.00 - 16.30
OR13-01

SHEDDING LIGHT ON NON-CODING 5' UTR VARIANTS ALTERING UPSTREAM OPEN READING FRAMES IN MAIN NATURAL COAGULATION INHIBITOR GENES.

Omar Soukarieh, France

16.30 - 16.45
OR13-02

GENOME-WIDE IDENTIFICATION OF LOCI CONTROLLING PLASMA COAGULATION FACTOR IX ACTIVITY.

Jihee Han, The Netherlands

16.45 - 17.00
OR13-03

GENOMIC LONG-READ SEQUENCING IDENTIFIES THE MOLECULAR BASIS OF UNDIAGNOSED PATIENTS WITH HEMOSTATIC DISORDERS: UNEXPECTED COMPLEX STRUCTURAL VARIANTS AND RETROTRANSPOSON INSERTIONS.

Belén de la Morena-Barrio, Spain

Thursday 14 September

16.00 - 16.45

Room: Auditorium 3

Focus Symposium - Aspects of von Willebrand Factor

*Moderators: Maria Aguiar (Portugal)
& Quintijn Bonnez (Belgium)*

16.00 - 16.30
OR14-01

NOVEL TREATMENTS FOR ACQUIRED VON WILLEBRAND SYNDROME DURING MECHANICAL CIRCULATORY SUPPORT DEVICE IMPLANTATION.
Karen Vanhoorelbeke, Belgium

16.30 - 16.45
OR14-03

THERAPEUTIC EFFICACY OF A NOVEL HUMANIZED ANTI-ADAMTS13 ANTIBODY TO TREAT LEFT VENTRICULAR ASSIST DEVICE-INDUCED ACQUIRED VON WILLEBRAND SYNDROME.
Deconinck Shannen, Belgium

Thursday 14 September

16.00 – 17.00

Room: Multifunctional A

**Focus Symposium –
Novel Laboratory Tests**

*Moderators: Waander van Heerde (The Netherlands)
& Claire Auditeau (France)*

16.00 - 16.15

OR15-01A

REPRODUCIBILITY STUDY OF A FAST AND FULLY
AUTOMATED FVIII FUNCTIONAL INHIBITOR TEST.

Nikolaus B. Binder, Austria

16.15 - 16.30

OR15-01B

FULLY AUTOMATED DETERMINATION OF APIXABAN,
EDOXABAN, RIVAROXABAN LEVELS USING A STANDARD
HEPARIN REAGENT ON COBAS T COAGULATION
ANALYZER.

Martina Leitner, Austria

16.30 - 16.45

OR15-02

PERFORMANCE OF THE LUMINESCENT-BASED ADAMTS13
ACTIVITY ASSAY.

Danique Steeghs, The Netherlands

16.45 - 17.00

OR15-03

MONITORING DIRECT ORAL ANTI COAGULANTS (DOAC) IN
A CHEMILUMINESCENT THROMBIN GENERATION ASSAY.

Mark van Geffen, The Netherlands

Thursday 14 September

16.00 - 17.00

Room: Multifunctional B

**Focus Symposium -
Inflammation and Haemostasis**

*Moderators: Anxhela Habibi (Germany)
& Pilar Medina Badenes (Spain)*

16.00 - 16.30 THE CENTRAL ROLE OF NEUTROPHIL EXTRACELLULAR
OR16-01 TRAPS IN DRIVING PLATELET HETEROGENEITY DURING
INFLAMMATION.

Julie Rayes, United Kingdom

16.30 - 16.45 DEVELOPMENT OF A MICROFLUIDIC MODEL TO EVALUATE
OR16-02 THE EFFICACY OF COMBINATION THERAPIES AGAINST
THROMBOINFLAMMATION IN THE MICROCIRCULATION.

Astride Perrot, France

16.45 - 17.00 POLYPHENOLS ATTENUATE INCREASED PLATELET-DERIVED
OR16-03 REACTIVE OXYGEN SPECIES (ROS) AND PLATELET
PROCOAGULANT ACTIVITY IN HYPERGLYCAEMIA.

Julia Sandrin Gauer, United Kingdom

Thursday 14 September

17.00 – 18.30

Main hall

Poster Session and Reception

Poster session information can be found on page 52

18.30 – 00.00

Congress Dinner

Carthusian Monastery *(offsite)*

Join us for an exceptional party at the former Carthusian Monastery, located just outside Valencia.

Enjoy Spanish dishes, drinks and dance the night away at this stunning location!

Busses will depart at 18:30 and return as of 22:00 from and back to the Valencia Conference Centre

Price: € 85 per person (to be purchased at the registration desk)

Friday 15 September

09.00 – 10.00

Room: Auditorium 2

Oral Communications: Clotting Structure & Function

*Moderators: Cédric Duval (United Kingdom)
& Julia Oto (Germany)*

- 09.00 – 09.15** DETECTION OF TFPI CITRULLINATION IN BLOOD AFTER
OR17-01 NEUTROPHIL ACTIVATION BY PMA.
Bryan Bouwens, The Netherlands
- 09.15 – 09.30** STRUCTURAL REARRANGEMENTS IN THE ADAMTS13 CUB
OR17-02 DOMAINS PERTURB THE ENZYME GLOBAL LATENCY.
Quintijn Bonneze, Belgium
- 09.30 – 09.45** FIBRIN'S ALPHAC-REGION ACTS AS A SECURITY LATCH AT
OR17-03 HIGH STRAINS BUT DOESN'T LEAD TO MAJOR ALTERATIONS
IN OVERALL MECHANICAL BEHAVIOUR OF FIBRES, AS
INDICATED BY ALPHA-TRUNCATED FIBRIN VARIANTS.
Timea Feller, United Kingdom
- 09.45 – 10.00** DESIGN AND CHARACTERIZATION OF NOVEL ACTIVATED
OR17-04 PROTEIN C (APC) VARIANTS FOR ENHANCED PROTEOLYSIS
OF HISTONE H3.
Joram Huckriede, The Netherlands

Friday 15 September

09.00 – 10.00

Room: Auditorium 3

**Oral Communications:
Venous & Arterial Thrombosis
Aspects and Risks**

*Moderators: Omri Snir (Norway)
& Jihee Han (NL)*

09.00 – 09.15 PLASMA LEVEL OF HUMAN EPIDIDYMISS PROTEIN
OR18-01 4 IS ASSOCIATED WITH RISK OF FUTURE VENOUS
THROMBOEMBOLISM.

Celina Janene Cathro, Norway

09.15 – 09.30 RISK OF CANCER AFTER VENOUS THROMBOEMBOLISM.
OR18-02

Camilla Langholm, Norway

09.30 – 09.45 GLUCOCORTICOID TREATMENT AND COAGULATION
OR18-03 PARAMETERS IN PATIENTS WITH A FIRST VENOUS
THROMBOSIS: DATA FROM THE MEGA STUDY.

Eleonora Camilleri, The Netherlands

09.45 – 10.00 DNASE-I OVERCOMES RT-PA RESISTANCE
OR18-04 OF PLATELET-RICH ISCHEMIC STROKE THROMBI.

Sarah Vandelanotte, Belgium

Friday 15 September

09.00 – 10.00

Room: Multifunctional A

**Oral Communications:
Regulation of Protein Function
in Hemostasis**

*Moderators: Ana Mendoza (Spain)
& Anastasis Petri (United Kingdom)*

09.00 – 09.15 SENSITIVE MEASUREMENT OF CLINICALLY RELEVANT
OR19-01 FACTOR VIII LEVELS IN THROMBIN GENERATION ASSAYS
REQUIRES PRESENCE OF FACTOR XIA.

Tom van de Berg, The Netherlands

09.15 – 09.30 IMPLEMENTING ANDEXANET ALFA IN THE HOSPITAL –
OR19-02 PRACTICAL EXPERIENCE AND LEARNING POINTS.

Melanie Acampo-de Jong, The Netherlands

09.30 – 09.45 PATIENTS WITH HEMOPHILIA A HAVE INCREASED LEVELS
OR19-03 OF CIRCULATING ACTIVATED PROTEIN C: POTENTIAL
CONTRIBUTION TO THEIR HEMOSTATIC STATUS.

Isabel Aleman-Cabrera, Spain

09.45 – 10.00 IDENTIFICATION OF FXI MONOMERS IN PLASMA: FUNCTION,
OR19-04 CLEARANCE AND RELEVANCE OF CYS339.

Juan José Rojo-Carrillo, Spain

Friday 15 September

09.00 – 09.45

Room: Multifunctional B

**Oral Communications:
Regulation of Coagulation
and Inflammation**

*Moderators: François Saller (France)
& Meghna Naik (United States)*

09.00 – 09.15 A SINGLE-DOMAIN ANTIBODY ENHANCING PROTEIN S
OR20-01 ACTIVITY REDUCES VASO-OCCLUSION IN TWO MURINE
MODELS OF SICKLE CELL DISEASE.

Claire Auditeau, France

09.15 – 09.30 IMPACT OF MIR-15A-5P ON GENE REGULATION IN
OR20-02 PRIMARY HUMAN MONOCYTES AND ENDOTHELIAL CELLS
AND MOUSE LIVER CELLS.

Parwez Ahmad, Norway

09.30 – 09.45 AN ANTICOAGULANT TICK SALIVARY PROTEIN INHIBITS
OR20-04 PLATELET ACTIVATION AND IMPAIRS IN VITRO THROMBUS
FORMATION.

Ingrid Dijkgraaf, The Netherlands

10.00 – 10.30 **Coffee Break and Poster Viewing**

Friday 15 September

10.30 - 11.30

State of the Art
Room: Auditorium 2

*Moderators: Zsuzsa Bagoly (Hungary)
& Timea Feller (United Kingdom)*

- 10.30 - 11.00** FIBRIN CLOT PROPERTIES AND THROMBOEMBOLISM.
Robert Ariens, United Kingdom
- 11.00 - 11.30** FIBRIN(OGEN) IN HUMAN DISEASE.
Marguerite Neerman-Arbex, Switzerland

State of the Art
Room: Auditorium 3

*Moderators: John-Bjarne Hansen (Norway)
& Bryan Bouwens (The Netherlands)*

- 10.30 - 11.00** CARDIOVASCULAR RISK FACTORS AND VENOUS
THROMBOEMBOLISM.
Sigrid Braekkan, Norway
- 11.00 - 11.30** NEUTROPHILS AT THE ACUTE PHASE OF ISCHEMIC STROKE.
Benoit Ho-Tin-Noe, France

Friday 15 September

11.30 – 12.30

Room: Auditorium 2

Science Fast and Furious

Moderator: Frits Rosendaal (The Netherlands)

11.30 – 11.45 RISK OF BLEEDING AND VENOUS THROMBOEMBOLISM
SFF02-01 IN PATIENTS UNDERGOING TOTAL HIP OR TOTAL KNEE
ARTHROPLASTY USING THERAPEUTIC DOSAGES OF
DOACS.

Mark Smeets, The Netherlands

11.45 – 12.00 TICAGRELOR PREVENTS STAPHYLOCOCCUS AUREUS
SFF02-02 INFECTIVE ENDOCARDITIS BY MITIGATING BACTERIAL
VIRULENCE.

Kirsten Leeten, Belgium

12.00 – 12.15 ANALYSIS OF THE TFPIA – PROTEIN S ANTICOAGULANT
SFF02-03 PATHWAY IN VIVO.

Anastasis Petri, United Kingdom

12.15 – 12.30 FLI-1 AS A MAJOR REGULATOR OF TALIN (TLN1)
SFF02-04 EXPRESSION IN MEGAKARYOCYTE AND PLATELETS.

Elisa Gabinaud, France

12.30 – 13.30 Lunch Break and Poster Viewing

Friday 15 September

13.30 - 14.30

Room: Auditorium 2

Plenary Lecture

*Moderators: Tilman Hackeng (The Netherlands)
& Rita Orbán-Kálmándi (Hungary)*

WOMEN AND THROMBOSIS.

**Sabine Eichinger, Medical University
of Vienna, Austria**

14.30 - 14.45

Closing ECTH 2023

Room: Auditorium 2

*Moderators: Pilar Medina (Spain) & Tilman Hackeng
(The Netherlands)*

Ceveron s100

AN EXPLOSION OF POSSIBILITIES


Discover our new Ceveron s100 analyzer with fully automated

technoclone



technoclone

ADAMTS13
FXIII activity
FVIII Inhibitor
Thrombin Generation
chromogenic assays
turbidimetric assays
clotting assays



The smallest coagulation analyzer fits within the palm of your hand

Learn more on
www.enzyre.com





Diagnostics is in our blood.



Haemostasis workflow solutions with CN-Series

Solutions empowered by
innovation for routine and
specialty testing



www.sysmex-europe.com

BLEEDING

P-001 – THE AXIS NETOSIS-ACTIVATED PROTEIN C MAY MODULATE THE HEMOSTATIC STATUS OF PATIENTS WITH HEMOPHILIA A.

Isabel Aleman-Cabrera, *IISLAFE, Spain*

P-002 – TWO RHEOLOGICAL MODES IN THE INJURY SITE.

Georgii Bykov, *Russian Academy of Sciences, Russian Federation*

P-004 – PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENT GIRLS WITH HEREDITARY BLEEDING DISORDERS.

Mohamed Elshinawy, *Alexandria University, Egypt*

P-005 – ACQUIRED VON WILLEBRAND SYNDROME IN THE SETTING OF UNEXPECTED MAJOR BLEEDING AFTER INVASIVE PROCEDURE: A DELAYED DIAGNOSIS.

Maria Aguiar, *Imuno Hemoterapy, Portugal*

P-006 – EVALUATION OF FVIII PK PROFILE IN KOREAN HEMOPHILIA A PATIENTS ASSESSED WITH MYPKFIT: A RETROSPECTIVE CHART REVIEW.

Eun Jin Choi, *Daegu Catholic University Medical Center, Republic of Korea*

P-007 – COMPARATIVE DIAGNOSTIC STUDY EVALUATING CLOT FORMATION BY ROTATIONAL THROMBOELASTOMETRY IN 63 PATIENTS WITH CONGENITAL DYSFIBRINOGENEMIA.

Tomas Simurda, *Comenius University in Bratislava, Slovakia*

P-008 – VALIDATION OF A FREEZING PROCEDURE FOR CHROMOGENIC FACTOR VIII REAGENTS.

Hassan Al Khmis, *Karolinska University Hospital, Sweden*

P-009 – HEMOPHILIA A USE CASE SCENARIOS FOR A PORTABLE TESTING DEVICE IN DIFFERENT REGIONS OF THE WORLD.

Anneke Sijbers, *Enzyre BV, the Netherlands*

P-010 – ROTATIONAL THROMBELASTOMETRY IN PERIOPERATIVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS.

Kristina Maria Belakova, *Comenius University in Bratislava, Slovakia*

P-011 – WHEN THERE IS NO AGE LIMIT: AN ELDERLY PATIENT WITH MELAENA, SEVERE ANEMIA AND EXTREME HEMOLYSIS.

Maria Mylona, *National and Kapodistrian University of Athens, Greece*

P-012 – THE CHALLENGE OF COAGULATION INHIBITOR THERAPY IN DENTISTRY – A COMMUNITY INTERVENTION PROJECT.

Claudia Coelho, *Unidade Local Saude do Nordeste, Portugal*

P-013 – CARDIOMETABOLIC RISK LEVEL OF PATIENT WITH HEMOPHILIA IN KOREA.

Hong Hoe Koo, *Korea Hemophilia Foundation, Republic of Korea*

CLOTTING

P-014 – THE PLASMA PROTEOME AND RISK OF VENOUS THROMBOEMBOLISM (VTE) .

Sigrid K. Brækkan, *The Arctic University of Norway, Norway*

P-015 – THE ASSOCIATION BETWEEN VENOUS THROMBOSIS-ASSOCIATED GENETIC VARIANTS AND COAGULATION FACTOR LEVELS AND THROMBIN GENERATION POTENTIAL.

Jihee Han, *Leiden University Medical Center, the Netherlands*

P-016 – BLADDER CANCER PATIENTS HAVE INCREASED NETOSIS AND IMPAIRED DNASEI-MEDIATED NET DEGRADATION THAT CAN BE THERAPEUTICALLY RESTORED IN VITRO.

Raquel Herranz, *The Health Research Institute Hospital La Fe, Spain*

P-017 – AGE AND SEX SPECIFIC RISKS OF MAJOR CARDIOVASCULAR COMPLICATIONS AND DEATH FOLLOWING ELECTIVE HIP AND KNEE ARTHROPLASTY IN THE NETHERLANDS: A DUTCH HOSPITAL DATA REGISTRY STUDY.

Mark Smeets, *Leiden University Medical Center, the Netherlands*

P-018 – APPLICATION OF COMPUTER-BASED METHODS TO DISCOVER AND OPTIMIZE BIOACTIVE COMPOUNDS WITH ANTI-INFLAMMATORY AND ANTI-ATHEROSCLEROTIC ACTIVITIES: FROM IN SILICO TO IN VIVO.
Kanin Wichapong, *Maastricht University, the Netherlands*

P-019 – THE INCREASED NETOSIS IN PLASMA OF PATIENTS WITH PERIPROSTHETIC JOINT INFECTION IS AGGRAVATED BY LOWER DNASEI ACTIVITY: POTENTIAL THERAPEUTIC INTERVENTION TO ELIMINATE THE BACTERIAL BIOFILM.
Raquel Herranz, *The Health Research Institute Hospital La Fe, Spain*

P-020 – COAGULATION EFFECTS OF INHIBITION OF FACTOR XA BY REVERSIBLE INHIBITORS ARE DIFFERENT FOR THE INTRINSIC AND EXTRINSIC ACTIVATION PATHWAYS OF FACTOR X.
Cornelis Kluff, *Good Biomarker Sciences, the Netherlands*

P-021 – SCREENING OF TRIPEPTIDE SUBSTRATES SPECIFIC TO BLOOD COAGULATION PROTEASES.
Elena Krivosheeva, *Enzyre, the Netherlands*

P-022 – INCREASED LEVELS OF NETOSIS-RELATED CYTOKINES IN PERITONEAL FLUID FROM ADVANCED HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS.
Julia Oto, *The Health Research Institute Hospital La Fe, Spain*

P-023 – WHICH SCORE WILL PREDICT THE BEST THE RISK OF FIRST THROMBOTIC EVENT IN CANCER WITH A HIGH RISK OF BLEEDING?
Teona Dumitru Dumitru, *CHU Saint Etienne, France*

P-024 – ALTERATIONS IN THROMBIN GENERATION AFTER SARS-COV-2 VACCINATION AND THE RELATION WITH INFLAMMATION.
William Van Dijk, *LUMC, the Netherlands*

P-025 – CHANGES IN THE PLASMA PROTEOME INDUCED BY A STANDARDIZED AUTOLOGOUS ACUTE PULMONARY EMBOLISM IN A PORCINE MODEL.
Vårin Eiriksdatte Wikan, *The Arctic University of Norway, Norway*

P-026 – THE ONSET OF THROMBOSIS IN DEEP VEINS (DVT): THE UNEXPECTED ROLE OF STRETCH AND SHEAR STRESSES ON ENDOTHELIAL CELLS.

Arianna Giannetti, *Centre de Biologie Structurale, France*

P-027 – RESTING HEART RATE AND RISK OF INCIDENT VENOUS THROMBOEMBOLISM.

Oda Leknessund, *Thrombosis Research Center, Norway*

P-028 – INCREASED THROMBIN GENERATION IN PATIENTS WITH ANTIBODY-MEDIATED REJECTION (ABMR) AFTER KIDNEY TRANSPLANTATION.

Linda Lóczi, *University of Debrecen, Hungary*

P-029 – UROLOGICAL CANCER PATIENTS DISPLAY AN INCREASE IN MARKERS OF HYPERCOAGULABILITY AND INFLAMMATION.

Isabel Aleman-Cabrera, *IISLAFE, Spain*

P-030 – NO DETECTABLE COAGULATION ACTIVATION AFTER VITAMIN K (MK-7) SUPPLEMENTATION IN PATIENTS ON DIALYSIS WITH FUNCTIONAL VITAMIN K DEFICIENCY: A ONE-YEAR RANDOMIZED, PLACEBO-CONTROLLED STUDY.

Else Marie Bladbjerg, *University Hospital of Southern Denmark, Denmark*

P-031 – ADIPOCYTE FATTY ACID-BINDING PROTEIN AND RISK OF FUTURE INCIDENT VENOUS THROMBOEMBOLISM.

Vania M. Morelli, *Arctic University of Norway, Norway*

P-032 – GENOME-WIDE GENETIC PREDICTORS OF PULMONARY EMBOLISM AMONG THOSE WITH A DEEP VEIN THROMBOSIS.

Nicholas L. Smith, *University Of Washington, United States*

P-033 – ELEVATED SERUM CONCENTRATION OF LIPOPROTEIN (A) IS ASSOCIATED WITH HYPOFIBRINOLYSIS IN PATIENTS WITH SEVERE AORTIC STENOSIS.

Magdalena Kopytek, *Jagiellonian University Medical College, Poland*

P-034 – MOLECULAR CHARACTERIZATION OF ANTITHROMBIN IN SAMPLES OF PATIENTS WITH DEFICIENCIES: A MASS SPECTROMETRY-BASED NEXT-GENERATION TEST.

Mirjam Kruijt, *Leiden University Medical Center, the Netherlands*

P-035 – IMPROVED SPECIFICITY OF ESTABLISHED ACTIVATED PARTIAL THROMBOPLASTIN TIME REAGENTS FOR LUPUS ANTICOAGULANT DETECTION.

Martin Unterberger, *Technoclone Herstellung von Diagnostika und Arzneimitteln, Austria*

P-036 – ALTERATIONS OF FIBRINOLYSIS IN SARS-COV-2 INFECTED PREGNANT WOMEN: A PROSPECTIVE, CASE-CONTROL STUDY.

Rita Orbán-Kálmándi, *University of Debrecen, Hungary*

P-037 – ROTATIONAL THROMBOELASTOMETRY (ROTEM) MEASUREMENTS FOR THE PREDICTION OF THROMBOLYSIS SAFETY IN ACUTE ISCHEMIC STROKE PATIENTS.

István Szegedi, *University of Debrecen, Hungary*

P-038 – CIRCULATING ACTIVATED PROTEIN C LEVELS ARE REDUCED IN CANCER PATIENTS, A NOVEL CONTRIBUTION TO TUMORIGENESIS?

Maria Castaño, *IISLAFE, Spain*

P-039 – STAPHYLOCOCCAL BIOFILMS: MOLECULAR SCAFFOLDS FOR THE ACTIVATION OF BLOOD COAGULATION.

Vincenzo De Filippis, *Università degli Studi di Padova, Italy*

P-040 – EKOSONIC ENDOVASCULAR SYSTEM PROMOTES THROMBOLYSIS BY ALTERING FIBRIN FIBRE THICKNESS AND CLOT PERMEABILITY.

Cédric Duval, *University of Leeds, United Kingdom*

P-041 – THE INCREASE IN PLASMA CELL-FREE DNA IN PATIENTS WITH VENOUS THROMBOEMBOLISM IS INDEPENDENT OF DNASE I ACTIVITY.

Raquel Herranz, *The Health Research Institute Hospital La Fe, Spain*

P-042 – FAMILIAL SEVERE THROMBOPHILIA COMBINED WITH INFERIOR VENA CAVA ANOMALY: HETEROZYGOUS ANTITHROMBIN BUDAPEST 3 MUTATION.

Nina Iversen, *Oslo University Hospital, Norway*

P-043 – IMPROVED DETECTION OF LUPUS ANTICOAGULANTS WITH NEW TAIPAN SNAKE VENOM TIME AND ECARIN TIME REAGENTS INSENSITIVE TO ANTICOAGULATION WITH VITAMIN K ANTAGONISTS, DIRECT FXA INHIBITORS, AND HEPARINS.

Gary Moore, *Technoclon Herstellung von Diagnostika und Arzneimitteln, Austria*

P-044 – COVID-19: CLOT PREVENTION IN HOSPITAL INPATIENTS.

Clarissa Pui, *Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom*

P-045 – EVALUATION OF DIGITAL MEASURING DEVICE WITH AN ADAMTS13 ACTIVITY SCREENING TEST.

Margaret Griffiths, *Technoclon Herstellung von Diagnostika und Arzneimitteln, Austria*

P-046 – AN OPTIMIZED THROMBIN GENERATION REAGENT SIGNIFICANTLY INCREASES SENSITIVITY FOR DETECTION OF THROMBOGENIC ACTIVITY IN IMMUNOGLOBULIN CONCENTRATES.

Helga Vetr, *Technoclon Herstellung von Diagnostika und Arzneimitteln, Austria*

P-047 – POST COVID 19 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME (CAPS): CASE REPORT IN PEDIATRICS.

Armando Estrada, *Hospital Benjamin Bloom, El Salvador*

P-048 – BILATERAL RENAL ARTERY PARADOXICAL EMBOLISM IN A PATIENT WITH CONCURRENTLY REVEALED UNKNOWN PATENT FORAMEN OVALE AND ANTIPHOSPHOLIPID SYNDROME.

Maria Mylona, *National and Kapodistrian University of Athens, Greece*

P-049 – INTRACARDIAC THROMBUS, A RARELY CARDIAC MANIFESTATION OF ANTITHROMBIN DEFICIENCY. IS SCREENING FOR CONGENITAL THROMBOPHILIA USEFUL?

Bounab Lyamine, *Regional Military University Hospital of Blida, Algeria*

P-050 – SINGLE-CENTER REAL-WORLD EXPERIENCE WITH IDARUCIZUMAB FOR DABIGATRAN REVERSAL.

Ana Mendoza, *Hospital Universitario La Paz, Spain*

P-051 – THE USEFULNESS OF CAPILLARY BLOOD COLLECTION DEVICES FOR COAGULATION PARAMETERS DETECTION IN HEMOPHILIA.

Lisa Van Engelshoven, *Enzyre, the Netherlands*

P-052 – HOW CAN WE BEST INFORM PATIENTS OF THE RISK FOR HOSPITAL ACQUIRED VTE? A COMPARISON OF PATIENT INFORMATION LEAFLETS AND RESULTS FROM A PATIENT SURVEY.

Aidan Haslam, *University Hospitals Birmingham, Afghanistan*

P-053 – REFINING THE DIAGNOSIS OF ANTITHROMBIN DEFICIENCY WITH NEXT-GENERATION PROTEIN DIAGNOSTICS AND MOLECULAR DEFINED (GLYCO)PROTEOFORMS.

Michelle P. van der Helm, *Leiden University Medical Center, the Netherlands*

P-054 – SEM AND 3D RECONSTRUCTION OF EX-VIVO ARTERIAL THROMBI: A PILOT STUDY.

Barbara Baráth, *University of Geneva, Switzerland*

P-055 – LUPUS ANTICOAGULANT: DOES A NORMAL CONFIRMATORY TEST VALUE NECESSARILY MEAN TIME CORRECTION?

Eleni Vagdatli, *Hippokration Hospital of Thessaloniki, Greece*

P-057 – THE FIRST ADMINISTRATION OF CAPLACIZUMAB IN THE FIRST LINE OF TREATMENT FOR ACQUIRED ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA IN SLOVAKIA.

Renata Pizurova, *National centre hemostasis and thrombosis, Slovakia*

P-062 – HETEROZYGOUS FV LEIDEN MUTATION ASSOCIATED WITH MULTIPLE CEREBRAL VENOUS THROMBOSIS IN CHILDHOOD. A CASE REPORT.

Yacine Larfi, *Central Hospital of Army, Algeria*

P-063 – EXPLORING TRANSCRIPTOME DIVERSITY OF HUMAN LIVER USING NANOPORE SEQUENCING.

Pedro Garrido Rodríguez, *CIBERER, Spain*

PLATELETS

P-065 – PLATELET F11R/JAM-A CONTRIBUTES TO PLATELET ADHESION UNDER FLOW CONDITIONS AND TO THROMBUS FORMATION.

Tomasz Przygodzki, *Medical University of Lodz, Poland*

P-067 – SPONTANEOUS PLATELET AGGREGATION ASSESSED BY LIGHT TRANSMITTANCE AGGREGOMETRY: AN ATTEMPT TO ESTABLISH LABORATORY REFERENCE INTERVALS.

Nikolaos Androulakis, *University Hospital of Heraklion, Greece*

P-068 – EXPERIENCE OF USING AVATROMBOPAG IN A TERTIARY HOSPITAL.

Raquel Iglesias, *Hospital Alvaro Cunqueiro, Spain*

P-069 – THE MEAN PLATELET VOLUME VALUES IN NEW INFLAMMATORY INDICES IN COVID-19 PATIENTS.

Athanasia Agorasti, *General Hospital of Xanthi, Greece*

P-071 – THE MECHANISMS OF PLATELET ACTIVATION IN INFLAMMATION.

Shaghayegh Rashvand, *University of Westminster, United Kingdom*

P-072 – DISTINGUISHING PATHOLOGICAL FROM PHYSIOLOGICAL ACTIVATION OF PLATELETS POTENTIATED BY EXERCISE.

Aleksandar Dishkelov, *University of Westminster, United Kingdom*



ECTH 2025
European Congress on
Thrombosis and Haemostasis

We are looking
forward **to welcome**
you again in 2025!